Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy

Lytic bone metastases are rare in prostate cancer. We here present 18 fluorine fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat (18)F-FDG PET-CT done 6 months later showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Punit, Karunanithi, Sellam, Singh Dhull, Varun, Jain, Sachin, Bal, Chandrasekhar, Kumar, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822421/
https://www.ncbi.nlm.nih.gov/pubmed/24250030
http://dx.doi.org/10.4103/0972-3919.119545
Descripción
Sumario:Lytic bone metastases are rare in prostate cancer. We here present 18 fluorine fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET-CT) images of a 67-year-old male patient with lytic metastases from prostate cancer. Repeat (18)F-FDG PET-CT done 6 months later showed response to medical castration therapy. While the role of (18)F-FDG PET-CT for sclerotic bone metastases in prostate cancer remains controversial, it appears to be useful for detection and response assessment of lytic prostate cancer metastases.

Ejemplares similares